Emerging therapeutic strategies targeting the p53 pathway, including reactivating mutant p53, inhibiting MYC-driven oncogenesis, and modulating immune responses, offer promising avenues for improving SCLC treatment outcomes. The gene discussed is TP53; the disease is small cell lung carcinoma.